Induction of sustained expression of proto-oncogene c-fms by platelet-derived growth factor, epidermal growth factor, and basic fibroblast growth factor, and its suppression by interferon-gamma and macrophage colony-stimulating factor in human aortic medial smooth muscle cells by Inaba Toshimori et al.
Induction of sustained expression of
proto-oncogene c-fms by platelet-derived
growth factor, epidermal growth factor, and
basic fibroblast growth factor, and its
suppression by interferon-gamma and macrophage
colony-stimulating factor in human aortic
medial smooth muscle cells
著者 Inaba Toshimori, Gotoda Takanari, Harada
Kenji, Shimada Masako, Ohsuga Jun-ichi,
Ishibashi Shun, Yazaki Yoshio, Yamada Nobuhiro
journal or
publication title
The journal of clinical investigation
volume 95
number 3
page range 1133-1139
year 1995-03
権利 (C) The American Society for Clinical
Investigation
URL http://hdl.handle.net/2241/102306
doi: 10.1172/JCI117761
Induction of Sustained Expression of Proto-oncogene c-fms by Platelet-derived
Growth Factor, Epidermal Growth Factor, and Basic Fibroblast Growth Factor,
and Its Suppression by Interferon-y and Macrophage Colony-stimulating
Factor in Human Aortic Medial Smooth Muscle Cells
Toshimori Inaba, Takanari Gotoda, Kenji Harada, Masako Shimada, Jun-ichi Ohsuga, Shun Ishibashi, Yoshio Yazaki, and
Nobuhiro Yamada
The 3rd Department of Internal Medicine, Faculty of Medicine, University of Tokyo, Hongo, Tokyo, 113, Japan
Abstract
Vascular medial smooth muscle cells migrate, proliferate
and transform to foam cells in the process of atherosclerosis.
We have reported that the intimal smooth muscle cells ex-
press proto-oncogene c-fms, a characteristic gene of mono-
cyte-macrophages, which is not normally expressed in me-
dial smooth muscle cells. In the present study, we demon-
strated that combinations of platelet-derived growth factor
(PDGF)-BB and either epidermal growth factor (EGF) or
fibroblast growth factor (FGF) induced high expression of
c-fms in normal human medial smooth muscle cells to the
level of intimal smooth muscle cells or monocyte-derived
macrophages, whereas c-fins expression by PDGF-BB alone
was 1/1o and both EGF and FGF had no independent effect
on c-fms expression. By contrast, interferon (IFN)-y and
macrophage colony-stimulating factor (M-CSF) suppressed
the induction of c-fins expression. These results indicate that
multiple growth factors and cytokines may play a role in the
phenotypic transformation of medial smooth muscle cells
to intimal smooth muscle cells in atherosclerotic lesions by
altering c-fins expression. (J. Clin. Invest. 1995. 95:1133-
1139.) Key words: c-fins * PDGF * EGF * M-CSF * smooth
muscle cell * atherosclerosis
Introduction
In atherosclerotic lesions, vascular smooth muscle cells undergo
structural and functional changes from a contractile to a syn-
thetic phenotype, in particular, transform into foam cells in the
intima by actively taking up lipoprotein cholesterol through
receptor-mediated endocytosis (1-3). We have previously
demonstrated that vascular smooth muscle cells isolated from
the intima of atherosclerotic lesions express, a characteristic
gene of monocyte-macrophages, c-fins (4), suggesting not only
that the mechanism underlying the process of atherosclerosis
induces alterations in the regulation of normal c-fins gene ex-
pression in vascular smooth muscle cells but also that factors
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inducing c-fins gene expression in vascular smooth muscle cells
play an important role in the process of atherosclerosis. Cells
expressing c-fis can respond to macrophage colony-stimulating
factor (M-CSF),' an 85-kD homodimeric glycoprotein, through
binding to specific high-affinity surface receptors encoded by
c-fins that constitute one member of a family of growth factor
receptors with intrinsic tyrosine kinase activity. The rapid phos-
phorylation at tyrosine initiates a cascade of metabolic and gene
regulatory events (5-8). The expression of the c-fins gene in
vascular smooth muscle cells initiates biological events includ-
ing cell surface binding of M-CSF, tyrosine-phosphorylation of
M-CSF receptor, and an increased rate of cell proliferation in
response to M-CSF, and vascular smooth muscle cells express-
ing c-fins transform into foam cells by taking up modified low
density lipoprotein (LDL) (4).
In atherosclerotic process, various cytokines and growth fac-
tors play important roles in phenotypic changes of vascular
smooth muscle cells (3). We have recently demonstrated that
platelet-derived growth factor (PDGF)-BB induces c-fins ex-
pression in medial smooth muscle cells, however, the induced
mRNA level of c-fims is transient and extremely low as com-
pared to its expression in monocyte-derived macrophages or
intimal smooth muscle cells isolated from the intima of athero-
sclerotic lesions (9). Our observations suggest that other growth
factors and cytokines in addition to PDGF-BB are required for
stable and high expression of c-fins in vivo. In the present study,
we investigated factors that are involved in the regulation of c -
fins expression in normal vascular smooth muscle cells, to define
the mechanism underlying the process of atherosclerosis.
Methods
Materials. Recombinant human PDGF-BB homodimer, recombinant
human epidermal growth factor (EGF), and recombinant human basic-
fibroblast growth factor (FGF) were purchased from Genzyme Co.
(Boston, MA). Recombinant human interferon (IFN)-y, and recombi-
nant human endothelin-1 were obtained from Shionogi Pharmaceutical
Co. (Osaka, Japan) and Peptide Institute Inc. (Osaka, Japan), respec-
tively. Recombinant human M-CSF was a purified product obtained
from Morinaga Milk Industry Co., Ltd. (Tokyo, Japan) (4, 9). Dibutyryl
cyclic AMP, insulin, PMA, pertussis toxin, cycloheximide, and stauro-
sporine were obtained from Sigma Chemical Co. (St. Louis, MO).
DME was obtained from GIBCO BRL (Gaithersburg, MD). All other
chemicals were of analytical grade.
Cells. Human aortic medial smooth muscle cells were explanted
from the human aorta by the method of Fischer-Dzoga et al. (9, 10).
1. Abbreviations used in this paper: CAT, chloramphenicol acetyltrans-
ferase; FGF, fibroblast growth factor; M-CSF, macrophage-stimulating
factor.
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The cells were passaged three times by trypsinization and seeded in 10
ml of DME containing 10% FCS in 100-mm dishes. Subconfluent cells
were cultured with 10 ng/ml PDGF-BB and various growth factors in
DME containing 1% FCS for 8 h at 37°C after a 24-h preincubation in
serum-free medium. Rabbit medial and intimal smooth muscle cells
were cultured and subconfluent cells were used for experiments as de-
scribed previously (4, 9). Monocytes were isolated from peripheral
blood of a normolipidemic healthy donor using the Ficoll-Hypaque
gradient method as described previously (11, 12). The cells were used
as monocyte-derived macrophages after 9 d of culture (13).
Quantitative analysis of M-CSF receptor mRNA and Northern blot
analysis. Total RNA was isolated from cultured smooth muscle cells
by the acid-guanidine phenol chloroform method (14). A competitive
PCR method was used to measure M-CSF receptor (c-fms) mRNA
levels as previously described (3, 15, 16). 1 jig of total RNA was
reverse-transcribed with random hexamer primers. The DNA fragment
of human c-fms gene (240 bp) was preparatively amplified with a pair
of primers and used in the competitive PCR as a control template.
Aliquots of the cDNA products were coamplified with indicated amounts
of the control genomic DNA (240 bp). The amplified fragments of
cDNA (164 bp) lack an intron.
Blot hybridization studies were performed for c-fins mRNA of hu-
man smooth muscle cells. 10 pig of total RNA was electrophoretically
fractionated on 1% (wt/vol) agarose/2.2 M formaldehyde gel and trans-
ferred onto a nylon membrane. The membrane was hybridized with the
cDNA probe for human c-fins (9). The filters were washed in 2x SSC
(lx SSC: 150 mM NaCl, 10 mM sodium citrate) and 0.5% (wt/vol)
SDS at room temperature for 15 min twice, then in 0.2x SSC and 0.5%
(wt/vol) SDS at 65°C for 15 min, and finally exposed to radiographic
films at -80°C.
Ribonuclease protection assay. A 1.2-kb Pst I fragment (2048-
3194) of the human c-fins cDNA was subcloned into pBluescript II SK
(-) (Stratagene Corp., La Jolla, CA), and this plasmid was digested
with Bgl II. The digested DNA was transcribed and labeled with [a-
32P] UTP (specific activity, 800 Ci/m mol; Amersham Corp., Arlington,
IL) using Riboprobe Gemini System according to the method described
in the instruction (Promega Corp., Madison, WI). A resultant 354-
bp antisense RNA probe was used for ribonuclease protection assay.
Ribonuclease protection assay was performed by the method described
in the instruction of Ribonuclease protection assay kit (Ambion Inc.,
Austin, TX). 10 pg of total RNA was hybridized with - 20,000 cpm
of the RNA probe overnight at 42°C, and then digested with the mixture
of RNase A and RNase Tl. A specific RNA for human c-fms that was
protected from digestion, was separated on a 8 M urea sequencing gel.
In vitro transcription assay. The bacterial chloramphenicol acetyl-
transferase (CAT) and the SV40 enhancer were isolated from pCAT-
control plasmid (Promega) as a 1.9-kbp HindlIl-SalI fragment. A 550-
bp Sacd fragment (-606 to -56) containing 5 ' non-coding region of c-fins
genomic DNA (17) was introduced into the pBS-CAT/SV40 plasmid
containing a 1.9-kbp HindIII-SalI fragment in pBluescript II KS(-)
(18), in a sense orientation immediately upstream of the CAT gene.
CAT plasmid and control ,6-galactosidase plasmid (pSV-/3-Gal) (Pro-
mega) were introduced into human aortic smooth muscle cells as fol-
lows; subconfluent cells, cultured on a 35-mm dish, were cotransfected
with lipofectin. Both CAT plasmid (1.5 mg) and pSV-f3-Gal (0.5 mg)
were mixed with 10 ml of Lipofectin Reagent (GIBCO BRL). After a
15-min incubation with foam lipid-DNA complex at room temperature,
the mixture was added to the culture medium of Opti-MEM I Reduced
Serum Medium (GIBCO BRL), which was exchanged just before trans-
fection. After 8 h, the culture medium was replaced by DMEM (GIBCO
BRL) containing 10% FCS. After 56 h, the medium was supplemented
with PDGF-BB (10 ng/ml) and/or EGF (3 ng/ml), and was incubated
subsequently for 4 h. The cells were harvested for measurement of CAT
(19) and /3-galactosidase activity as described by Herbomel et al. (20).
In brief, transfected cells were washed three times with phosphate-
buffered saline, scraped into 500 p1 of the lysis buffer of 40 mM Tris-
HCI buffer, pH 7.4, containing 1 mM EDTA and 150 mM NaCl, lysed
by shearing through a 25-gauge needle 10 times, and centrifuged at
14,000 g for 2 min at 4°C. An aliquot of the supermatant (20 jg) was
incubated for 1 h at 37°C in a standard CAT assay in a final volume
of 0.15 ml of containing 0.9 nmol of ['4C]chloramphenicol (50 nCi)
(Amersham) and 0.53 mM butyryl-CoA. All assays were linear with
respect to incubation time and concentration of extract protein. The
reaction products were chromatographed on Merck 5748 silica gel plates
developed in a chloroform/methanol (95:5 vol/vol) solvent system, and
finally exposed to radiographic films at -80°C. Then, butyrated products
were scraped and counted. Each cell lysate was simultaneously analyzed
for CAT enzyme activity and control plasmid /3-galactosidase activity.
The measured CAT activity was normalized relative to /3-galactosidase
activity.
DNA synthesis and uptake of acetylated LDL. Subconfluent cells
were used, and medium was replaced with serum-free RPMI 1640 for
48 h before the experiment. After incubating with human PDGF-BB
and/or human EGF in RPMI 1640 containing 1% fetal calf serum for
24 h, 1 pCi/ml of [3H]thymidine ( 1 mCi/ml; NEN Research Products,
Boston, MA) was added. Incubation was performed for 4 h, and then
the radioactivity in the cells was determined (4).
LDL (d = 1.019-1.063 g/ml) was prepared from human plasma
containing 0.1% EDTA, 0.02% sodium azide, and 0.5 mg/ml benzami-
dine, from fasted normolipemic volunteers, and isolated by sequential
ultracentrifugation in a 50.2 Ti rotor (Beckman Instruments, Palo Alto,
CA) as described previously (21, 22). LDL was acetylated by repetitive
additions of acetic anhydride ( 13, 23 ) and lipoproteins were radioiodin-
ated with Na 1251 using the iodine monochloride method (24, 25). Sub-
confluent cells were cultured with PDGF-BB and/or EGF in DME
containing 1% FCS for 8 h at 37°C after a 24-h preincubation in serum-
free medium, and further incubated with PDGF-BB and/or EGF in the
presence of 10 pg/ml '25I-acetylated LDL for 5 h at 37°C to study cell
association and degradation of '25I-acetylated LDL. Cell association
and degradation of '25I-acetylated LDL were determined by the method
described previously ( 13, 26). Nonspecific cell association and degrada-
tion were determined by the addition of a 50-fold excess of unlabeled
acetylated LDL.
Results
c-fins mRNA analysis. The mRNA of c-fims was not detected
in human aortic smooth muscle cells using northern blot hybrid-
ization with a cDNA probe of c-fins as we reported (4, 9).
Even when 10 ng/ml PDGF-BB induced the gene expression
of c-fins in human aortic smooth muscle cells, mRNA was not
detected in northern blot hybridization (9). In the presence of
both 3 ng/ml EGF and 10 ng/ml PDGF-BB, mRNA of c-
fins was detected in human aortic smooth muscle cells as a
comparable mRNA level to that in human monocyte-derived
macrophages (Fig. 1 A). However, c-fins expression was not
induced by these growth factors in human skin fibroblasts (un-
published observation).
To estimate the mRNA level of c-fins, we used a sensitive
competitive polymerase chain reaction method. In this assay,
the amplified fragments of cDNA (164 bp) were shorter than
those of genomic DNA (240 bp) due to lack of an intron (Fig.
1 B). Since cDNA and genomic DNA fragments can be coam-
plified with the same set of primers and their sizes are different,
coamplification of the two fragments should occur in a concen-
tration-dependent manner. It is possible to quantitate the amount
of cDNA present, by titrating an unknown amount of cDNA
against a dilution series containing known amounts of the corre-
sponding genomic DNA. For instance, the same amounts of
genomic DNA and cDNA fragments were obtained when the
concentration of genomic template (240 bp) was 8 X 10-2 pg/
,ul in the assay for the estimation of c
-fins mRNA level in
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Figure 1. Northem blot hybridization analysis (A) and quantitative anal-
ysis (B) of M-CSF receptor mRNAs isolated from human aortic medial
smooth muscle cells. Human aortic medial smooth muscle cells were
explanted from the human aorta. Subconfluent cells were cultured with
10 ng/ml human PDGF-BB and 3 ng/ml human EGF in DMEM con-
taining 1% FCS for 8 h after a 24 h preincubation in serum-free medium.
Thereafter, 10 Isg of total RNA was applied to Northern blot hybridiza-
tion with the cDNA probe for human c-fins. A competitive polymerase
chain reaction method was used to measure M-CSF receptor (c-fins)
mRNA levels. 1 isg of total RNAs isolated from the cells was reverse-
transcribed with random hexamer primers. Aliquots of the cDNA prod-
ucts were coamplified with indicated amounts of the control genomic
DNA (240 bp). mRNA levels were estimated by titrating an unknown
amount of cDNA (164 bp) against a dilution series containing known
amounts of the corresponding genomic DNA.
human aortic smooth muscle cells in the presence of 10 ng/ml
PDGF-BB and 3 ng/ml EGF (Fig. 1 B).
In assays of human aortic smooth muscle cells in the pres-
ence of PDGF-BB only, the mRNA levels were estimated at 8
X 10-3 pg/,al genomic DNA (240 bp). These results indicate
that the transcription of c-fims in human aortic smooth muscle
cells was increased 10-fold in the presence of both PDGF-BB
and EGF compared to PDGF-BB alone and that the induced
mRNA level was comparable to those of human monocyte-
derived macrophages and rabbit intimal smooth muscle cells (8
x 10-2 versus 17.5 X 10-2 and 10 X 10-2 pg/pl, respectively,
Table I). In agreement with these results, ribonuclease protec-
tion assay demonstrated that mRNA level of c-fins in human
medial smooth muscle cells in the presence of both PDGF-BB
and EGF was comparable to that in human monocyte-derived
macrophages (data not shown).
We have previously reported that PDGF-AA, interleukin
(IL)-1,/, IL-3, tumor necrosis factor-a, insulin, endothelin-1,
interferon--y, noradrenalin, transforming growth factor-,6, phor-
bol ester, and dibutyryl cyclic AMP do not induce c-fins expres-
sion (9). In the present study, we further found that 3 ng/ml
EGF, 80 ng/ml IL-2, 10 ng/ml IL-4, 25 ng/ml IL-6, and 3 ng/
ml basic FGF did not induce c-fins expression in human aortic
medial smooth muscle cells using a sensitive competitive PCR
method.
We observed that 10 ng/ml PDGF-BB and 3 ng/ml EGF
induced the expression of c-fims 8 to 12 h after their addition
into the culture medium (Fig. 2 A), and gene expression was
enhanced 103 to 104-fold in response to both PDGF-BB and
EGF in human aortic smooth muscle cells. This enhanced ex-
Table l. mRNA Expression of c-fins in Vascular Smooth
Muscle Cells
mRNA level
(10-2 pg/4l) Fold
Human monocyte-derived macrophage 17.5 1.0
Human aortic medial SMC 0.002 1.1 X 10-4
Rabbit aortic medial SMC 0.001 0.6 x 10-4
Rabbit aortic intimal SMC 10.0 0.6
Rabbit intimal smooth muscle cells (SMC) were isolated from intima
of balloon-injured aorta (4), and human monocyte-derived macrophages,
human and rabbit aortic medial SMC were cultured as described in
Methods. Total RNA was isolated from cells and levels of mRNA
expression were estimated by a competitive polymerase chain reaction
method and expressed as genomic c-fins concentrations (10-2 pg/Ul).
pression of c-fins was sustained at least 48 h after exposure to
both PDGF-BB and EGF as compared to that by PDGF-BB
alone. The effect of PDGF and EGF on c-fins expression was
dose-dependent on concentrations of EGF (Fig. 2 B). The
amounts of RNA/cell were not significantly different among
untreated cells, cells treated with PDGF alone, and cells treated
with PDGF and EGF. In addition to EGF, 3 ng/ml basic-FGF
and 100 nM PMA enhanced the effect of PDGF-BB on c-
fins expression (Table II), whereas insulin, endothelin-1, and
dibutyryl cyclic AMP had no additional effect on c-fins expres-
sion induced by PDGF-BB (Tables II and III). Pretreatment of
aortic smooth muscle cells with PMA for 24 h or staurosporine
suppressed c-fins expression in the presence of both PDGF-BB
and EGF to half of that in controls (Table III). As shown in
Table III, pertussis toxin did not influence it, suggesting that
pertussis toxin-sensitive G protein was not involved in the en-
hanced expression of c-fins.
In contrast, c-fins mRNA levels in human aortic smooth
muscle cells were only 8 x 10-4 pg/'41 in the presence of a
combination with 10 ng/ml PDGF-BB and 50 units/ml IFN-y
and 1.6 x 10-3 pg/fl in the presence of a combination with
10 ng/ml PDGF-BB and 50 ng/ml M-CSF (Table II). These
results indicated the mRNA levels of c-fins in the presence of
IFN-y and M-CSF were 1/1o and '/5 that of PDGF-BB alone,
respectively (8 x 10-4 and 1.6 x 10-3 versus 8 x I0-3 pg/ Il,
respectively). The addition of EGF reduced the inhibitory effect
of M-CSF on mRNA expression of c-fins as compared to in
the absence of EGF (Table III).
To study the effect of protein synthesis inhibition on c-
fins expression by IFN-y, subconfluent vascular smooth muscle
cells were preincubated with 50 Hg/ml cycloheximide for 15
min before the experiment and further incubated with 50 MLg1
ml cycloheximide in the presence of both 10 ng/ml PDGF-BB
and 50 units/ml IFN-y in DMEM containing 1% FCS for 8 h
after a 24-h preincubation in serum-free medium. 50 pg/ml
cycloheximide did not influence the inhibitory effect of IFN-y
on c-fins expression.
In vitro transcription study. A 0.55-kb SacI fragment (-606
to -56) containing 5' non-coding region of c-fms genomic DNA
was introduced immediately upstream from the CAT gene (Fig.
3 A). Since the 0.55-kb SacI fragment was reported to have no
enhancer activity (17), an exogenous viral enhancer, the SV40
core enhancer, was introduced into CAT plasmid. The promoter
constructs were transiently transfected into human aortic smooth
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muscle cells. These cells showed high CAT activity in the pres-
ence of 10 ng/ml PDGF-BB (Fig. 3, B and C). Furthermore,
in the presence of both 10 ng/ml PDGF-BB and 3 ng/ml EGF,
CAT activity was enhanced twofold as compared to PDGF-BB
alone. The EGF effect on CAT activity was less than that on
c-fins expression demonstrated as mRNA levels, because a full-
length of c-fims gene may be required to see the full effect of
EGF on c-fins expression.
DNA synthesis and scavenger receptor activity. To charac-
terize the effects of PDGF-BB and EGF on cellular functions,
we studied [3H]thymidine incorporation into DNA. As shown
in Table IV, 10 ng/ml PDGF-BB, 3 ng/ml EGF and both stimu-
lated the [3H]thymidine incorporation into DNA by 2.6-, 1.5-,
and 4.7-fold, respectively, whereas IFN-y suppressed the effect
of PDGF-BB.
Table II. Effects of Various Factors on mRNA Expression of c-fins
in the Presence of PDGF-BB in Human Aortic Medial Smooth
Muscle Cells
mRNA level Fold*
No addition 0.8 1.0
EGF (3 ng/ml) 8.0 10.0
Basic-FGF (3 ng/ml) 4.0 5.0
Insulin (100 nM) 0.8 1.0
Endothelin 1 (100 nM) 0.8 1.0
PMA (100 nM) 12.0 15.0
Dibutyryl cyclic AMP (1 mM) 0.8 1.0
IFN-y (50 units/ml) 0.08 0.1
M-CSF (50 ng/ml) 0.16 0.2
Subconfluent human aortic medial smooth muscle cells were cultured
with 10 ng/ml PDGF-BB and the indicated factors in DMEM containing
I% FCS for 8 h after a 24 h preincubation in serum-free medium.
Thereafter, total RNA was isolated and levels of mRNA expression
were estimated by a competitive polymerase chain reaction method and
expressed as genomic c-fins concentrations ( 10-2 pg/,l). * As compared
to no addition.
Furthermore, we estimated cell association and degradation
of acetylated LDL in human medial smooth muscle cells. As
shown in Fig. 4, acetylated LDL was degraded by medial
smooth muscle cells in response to 10 ng/ml PDGF-BB and 3
ng/ml EGF in the presence of 10 j[g/ml acetylated LDL (Fig.
4), and a combination of PDGF-BB and EGF enhanced cell
association and degradation of acetylated LDL as compared to
either PDGF-BB or EGF alone. Whereas no cell association
and degradation of acetylated LDL was demonstrated in the
absence of those growth factors as we previously reported (4).
Table IlI. Effects of Various Treatments in the Presence of Both
PDGF-BB and EGF on mRNA Expression of c-fins in Human
Aortic Medial Smooth Muscle Cells
mRNA level Fold1
102 pg/gl
PDGF-BB (10 ng/ml) and EGF (3 ng/ml)
No treatment 8.0 1.0
PMA preincubation* 4.0 0.5
Staurosporine (50 nM)I 4.0 0.5
Pertussis toxin (10 ng/ml)§ 8.0 1.0
M-CSF (50 ng/ml)1I 6.0 0.75
Subconfluent human aortic medial smooth muscle cells were cultured
with both 10 ng/ml PDGF-BB and 3 ng/ml EGF in DMEM containing
1% FCS for 8 h after a 24 h preincubation in serum-free medium.
* Cells were preincubated with 100 nM PMA for 24 h before the experi-
ment. t Cells were preincubated with 50 nM staurosporine for 30 min
before the experiment and further incubated with 50 nM staurosporine
for 2 h. § Cells were preincubated with 10 ng/ml pertussis toxin for 24
h before the experiment and further incubated with 10 ng/ml pertussis
toxin for 8 h. 11 Cells were cultured with 50 ng/ml M-CSF in addition
to 10 ng/ml PDGF-BB and 3 ng/ml EGF 8 h after a 24 h preincubation
in serum-free medium. Thereafter, total RNA was isolated and levels
of mRNA expression were estimated by a competitive polymerase chain
reaction method and expressed as genomic c-fins concentrations (10'
pg/il). I As compared to no treatment.
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Figure 3. In vitro transcription
assay. A 550-bp Sacd fragment
(-606 to -56) containing 5' non-
coding region of c-fins genomic
DNA was introduced into the
pBS-CAT/SV40 plasmid in a
sense orientation immediately up-
stream of the CAT gene. CAT
plasmid and control /3-galactosi-
dase plasmid (pSV-,B-Gal) were
introduced into subconfluent hu-
man aortic smooth muscle cells
with lipofectin on a 35-mm dish.
Transfected cells were cultured
with PDGF-BB (10 ng/ml) and/
or EGF (3 ng/ml) for 4 h and then
cells were harvested for measure-
ment of CAT and /3-galactosidase
activity. The measured CAT activ-
ity was normalized relative to ,/-
galactosidase activity. The results
for each CAT plasmid tested rep-
resent the mean±SD for three
assays.
Discussion
Various cytokines and growth factors secreted by vascular cell
components including endothelial cells, monocyte-macro-
phages, smooth muscle cells, and lymphocytes, are presumed
to play important roles in the phenotypic change of vascular
smooth muscle cells in an autocrine or paracrine manner (3).
Among these factors, the present study demonstrated that a
combination of PDGF-BB and either EGF or FGF induced c-
fins expression in vascular medial smooth muscle cells which
do not normally express c-fins (4), causing c-fins expression
to become equivalent to those of human monocyte-derived mac-
rophages and rabbit intimal smooth muscle cells isolated from
atherosclerotic lesions, whereas c-fims expression by PDGF-BB
alone was transient and low, and both EGF and FGF had no
Table IV. Effects of PDGF-BB, EGF, and IFN--y on Cell Growth
in Human Aortic Medial Smooth Muscle Cells
[3H]Thymidine
uptake %
dpm/mg cell protein
No addition 18355±1380 100
10 ng/ml PDGF-BB 48068±569 262
3 ngml EGF 26686±1149 145
50 units/ml IFN-y 13696±1761 75
10 ng/ml PDGF-BB + 3 ng/ml EGF 85308±7583 465
10 ng/ml PDGF-BB + 50 units/ml IFN-y 27998±2139 153
Smooth muscle cells were seeded at a density of 105 cells/ml and me-
dium was replaced with serum-free RPMI 1640 for 48 h before the
experiment. After incubating with human PDGF-BB, human EGF, and/
or human IFN-y in RPMI 1640 containing 1% fetal calf serum for 24
h, [3H]thymidine was added, and incubation was performed for 4 h. The
radioactivity in the cells was then determined. Each value represents
the mean±SD of triplicate wells.
independent effect on c-fins expression. A combination of
PDGF-BB and EGF enhanced not only c-fins expression but
also thymidine incorporation and scavenger receptor activity. It
has been suggested that PDGF-BB acts initially to render cells
competent to respond to progression factors (27, 28). Progres-
sion factors such as EGF and FGF not only stimulated the
signal induced by PDGF-BB but also functioned to keep c-
fins expression high, resulting in the acceleration of phenotypic
transformation of medial smooth muscle cells to intimal smooth
muscle cells.
In addition, PMA, which is an activator of protein kinase C,
enhanced the effect of PDGF-BB. This indicates that stimulative
effects of either EGF or FGF in combination with PDGF-BB
on c-fins expression may result from protein kinase C activation.
Previous studies have shown that prolonged exposure of cells
to PMA makes cells refractory to PMA, because protein kinase
C activity in PMA-treated cells is down-regulated (29-31).
Pretreatment of aortic smooth muscle cells with PMA or stauro-
sporine (protein kinase C inhibitors) suppressed c-fins expres-
sion in the presence of both PDGF-BB and EGF to only half
of that in controls (Table I). These data suggest that the effect
of EGF in combination with PDGF-BB can not only be attrib-
uted to protein kinase C activation. We have reported that the
c-fins expression by PDGF-BB alone is not mediated through
protein kinase C activation because PMA alone did not induce
c-fins expression and H7 and staurosporine demonstrated no
effects on c-fins expression by PDGF-BB (9). Therefore, c-fms
expression is induced initially by PDGF-BB-specific pathways
independent of protein kinase C and then augmented by EGF
and FGF through both protein kinase C-dependent and -inde-
pendent pathways. Furthermore, additions of either dibutyryl
cyclic AMP to PDGF-BB (Table II) or pertussis toxin to a
combination of PDGF-BB and EGF (Table III) had no effects
on c-fins expression, indicating that neither cAMP dependent
pathway nor pertussis toxin sensitive G protein were involved
in sustained and high expression of c-fims in the presence of
PDGF-BB.
We demonstrated that IFN-y and M-CSF inhibited the in-
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Figure 4. Specific cell association and degradation of '25I-acetylated
LDL. Subconfluent medial smooth muscle cells were cultured with 10
ng/ml PDGF-BB and/or 3 ng/ml EGF for 8 h after a 24 h preincubation
in serum-free medium, and further incubated with PDGF-BB and/or
EGF in the presence of 10 jig/ml 1251I-acetylated LDL for 5 h at 37°C.
Then cell association and degradation of '25I-labeled lipoproteins were
determined. Nonspecific cell association and degradation were deter-
mined by the addition of a 50-fold excess of unlabeled lipoproteins and
were subtracted from total cell association and degradation. Each value
represents the mean of triplicate wells.
isolated from atherosclerotic lesions, and proposed that these
gene expressions may be related to the phenotypic conversion
of vascular smooth muscle cells to foam cells in atheromatous
lesions (4, 9, 44-47). Furthermore, recent studies have demon-
strated that PDGF-BB induces scavenger receptor expression
in normal medial smooth muscle cells through protein kinase
C activation (9, 44) and IFN-y suppresses scavenger receptor
activity (33, 34). In the present study, we demonstrated that
EGF also induced scavenger receptor activity in human aortic
medial smooth muscle cells and that a combination of EGF and
PDGF-BB had an additive effect on scavenger receptor activity.
Since EGF as well as PDGF-BB is a potent activator of protein
kinase C, EGF may induce scavenger receptor activity through
the activation of protein kinase C.
Many growth factors and cytokines regulate cellular func-
tions of vascular wall to maintain its homeostasis and play a
role in the progression or regression of atherosclerosis. In the
present study, we demonstrated that multiple growth factors
are involved in the regulation of c-fins expression via certain
signaling pathways in an autocrine or paracrine manner, how-
ever, each growth factor and cytokine except PDGF-BB had no
independent effect on c-fins expression. The expression of c-fins
may explain characteristic aspects of transformation of vascular
smooth muscle cells to phagocytic phenotype. Since gene ex-
pression of c-fins in smooth muscle cells coincides with the
phenotypic conversion of medial smooth muscle cells to intimal
smooth muscle cells, c-fins induction by different growth factors
in vascular smooth muscle cells may serve as a good model to
study complex interactions of growth factors and cytokines in
the arterial wall.
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